FGF21 Mutants and Uses Thereof
AssigneeAmgen Inc.
InventorsEdward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
Life of this patent
Estimating the term…
Abstract
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Claims25
A method of treating cardiovascular disease comprising administering to a human patient in need thereof a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:
- 4 and comprising (a) a substitution of an arginine, cysteine, glutamic acid, glutamine, lysine, or threonine residue for the leucine residue at position 98, or (b) a substitution of an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine, serine, threonine, tryptophan, or tyrosine residue for the proline residue at position 171 or a combination of (a) and (b).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
24-50. (canceled)
Dependencies are inferred from the claim text.